Biological Causes
The primary driver of this condition is the male hormone testosterone (and other androgens), which signals prostate cancer cells to grow and multiply. In metastatic castration-sensitive prostate cancer, these cells have escaped the prostate and traveled through the bloodstream or lymphatic system to other areas, such as the bones or lymph nodes. Despite spreading, the cancer cells remain dependent on testosterone for survival, which is why they respond to treatments that deplete this hormone.

Risk Factors
Several factors increase the likelihood of developing advanced prostate cancer:

• Age: The risk increases significantly as men get older, particularly after age 50.
• Race and Ethnicity: Men of African ancestry are at a higher risk of developing aggressive forms of prostate cancer compared to men of other racial backgrounds.
• Family History: Having a father or brother with prostate cancer, especially if diagnosed young, increases risk.
• Genetics: Inherited mutations in certain genes, such as BRCA1 or BRCA2, are linked to more aggressive prostate cancer.

Prevention
There is no guaranteed way to prevent prostate cancer from developing or spreading, but early detection is the most effective strategy for avoiding metastatic disease. Regular screening with Prostate-Specific Antigen (PSA) blood tests can identify cancer while it is still localized to the prostate. Maintaining a healthy weight, exercising regularly, and eating a diet rich in fruits and vegetables may help reduce overall cancer risk, though their specific impact on preventing metastasis is still being studied.

Signs and Symptoms
In the early stages of metastasis, some men may not experience noticeable symptoms, but as the disease progresses, specific signs often appear. Symptoms can be related to the prostate itself or to the areas where the cancer has spread:

• Bone pain, often felt in the back, hips, ribs, or shoulders.
• Urinary problems, such as a weak stream, frequent urination, or blood in the urine.
• Unexplained weight loss and fatigue.
• Swelling in the legs or feet due to lymph node involvement.

How It Is Diagnosed
Clinicians use a combination of laboratory tests and imaging to diagnose this condition. A high PSA level is usually the first indicator. Diagnosis is confirmed through:

• Biopsy: Tissue samples from the prostate or a metastatic site are analyzed to confirm the presence of cancer cells.
• Imaging Scans: Bone scans, CT scans, and MRI scans are used to visualize where the cancer has spread.
• PSMA PET Scans: A specialized and highly sensitive imaging test that detects prostate cancer cells throughout the body using a radioactive tracer.

Medications and Systemic Therapy
The cornerstone of treatment is Androgen Deprivation Therapy (ADT), also known as hormone therapy. This treatment lowers testosterone to very low levels, starving the cancer cells. Modern standard of care involves combining ADT with other powerful medicines to control the disease more effectively:

• Novel Hormone Therapies: Drugs like abiraterone, enzalutamide, or apalutamide block the action of androgens more completely.
• Chemotherapy: Medications such as docetaxel may be used alongside hormone therapy, especially for patients with a high volume of disease.

Procedures
In some cases, radiation therapy directed at the primary tumor in the prostate can improve survival, particularly for men with a lower volume of metastases. Radiation may also be used to relieve pain in specific bone areas.

Lifestyle and Management
Managing the side effects of hormone therapy is a critical part of care. Regular exercise, particularly resistance training, helps counteract muscle loss and fatigue. Calcium and Vitamin D supplements are often recommended to protect bone health, as hormone therapy can weaken bones.

When to Seek Medical Care
Patients should contact their healthcare provider if they experience new or worsening bone pain, difficulty urinating, or leg weakness/numbness, which could indicate spinal cord compression. Regular follow-up appointments are essential to monitor PSA levels, which indicate how well the treatment is working.

Severity and Disease Course
Metastatic castration-sensitive prostate cancer is a severe, Stage IV condition because the cancer has spread to distant parts of the body. However, because it is "castration-sensitive," it is highly responsive to treatment. The disease typically follows a course where it is controlled for a period ranging from several months to many years. Eventually, the cancer cells may adapt and grow despite low testosterone levels, a state known as castration-resistant prostate cancer.

Prognosis Factors
Survival rates vary significantly based on the volume of disease (how many metastases are present) and the specific treatment combination used. Men with "low volume" disease generally have a better prognosis than those with extensive spread to bones or internal organs. While the condition is not curable, the introduction of intensified combination therapies has extended the average life expectancy significantly compared to hormone therapy alone.

Complications
Long-term risks include osteoporosis and bone fractures due to hormonal changes. The cancer itself can cause complications like spinal cord compression or blockage of the urinary tract, which require immediate medical attention.

Impact on Daily Activities
Living with this condition involves adapting to both the cancer and the side effects of treatment. Men may experience fatigue, hot flashes, decreased libido, and mood changes due to low testosterone. These physical changes can affect energy levels for work and hobbies. Staying active and prioritizing rest when needed are practical coping strategies.

Mental and Emotional Health
A diagnosis of metastatic cancer can cause anxiety or depression. Many men find it helpful to join support groups where they can share experiences with others facing similar challenges. Open communication with a partner is also important, as the diagnosis and treatment often impact sexual intimacy.

Questions to Ask Your Healthcare Provider
Patients can bring this list of questions to their appointments to better understand their care:

• Is my disease considered high volume or low volume, and how does that change my treatment?
• What combination of therapies is best for my specific situation?
• Should I undergo genetic testing to see if there are targeted treatments available?
• What are the potential side effects of these medications, and how can we manage them?
• How will we know if the treatment stops working?

Q: Is metastatic castration-sensitive prostate cancer curable?
A: It is generally not considered curable because the cancer has spread to other parts of the body. However, it is highly treatable, and many men live for years with the disease under control.

Q: What does "castration-sensitive" mean?
A: This term means that the cancer cells still rely on testosterone to grow. Therefore, treatments that lower testosterone levels (medical castration) are effective at stopping or slowing the cancer.

Q: Will I need chemotherapy?
A: Not everyone needs chemotherapy. It is often used for men with a high volume of metastases, but many patients are treated effectively with a combination of hormone therapy and oral medications.

Q: Does this condition run in families?
A: While most cases are sporadic, some are linked to inherited genetic mutations. If you have a strong family history of cancer, your doctor may recommend genetic testing.

Q: How is this different from castration-resistant prostate cancer?
A: Castration-sensitive cancer stops growing when testosterone is lowered. Castration-resistant cancer has adapted to grow even when testosterone levels are extremely low.